Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. PLx Pharma Inc.
  6. Company
    PLXP   US72942A1079

PLX PHARMA INC.

(PLXP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo PLx Pharma Inc.
PLx Pharma Inc. is a late-stage specialty pharmaceutical company. It is focusing on developing clinically-validated and patent-protected PLxGuard delivery system. Its lead product, Vazalore 325 mg, which is a formulation of aspirin using the PLxGuard delivery system intended to provide antiplatelet for cardiovascular disease prevention as compared to the current standard of care, enteric-coated aspirin, and significantly reduce gastric side effects. The Company has also developed Vazalore 81 mg, a lower-dose companion product for Vazalore 325 mg. The PLxGuard delivery system uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs to selectively release these drugs to targeted portions of the GI tract. Its product pipeline also includes other oral NSAIDs using the PLxGuard delivery system that may be developed, including a clinical-stage, GI-safer ibuprofen, PL1200 Ibuprofen 200 mg, for pain and inflammation.

Number of employees : 11 people.
Sales per Business
20192020Delta
PLxGuard Drug Delivery Platform0.57100%0.03100% -94.62%
USD in Million
Sales per region
20192020Delta
United States0.57100%0.03100% -94.62%
USD in Million
Managers
Name Title Age Since
Natasha Giordano President, Chief Executive Officer & Director 59 2016
Rita M. O'Connor CFO, Head-Manufacturing & Supply Chain 51 -
Gary S. Balkema Independent Director 65 2016
Kirk K. Calhoun Independent Director 76 2016
Robert Daniel Casale Independent Director 61 2016
John W. Hadden Independent Director 50 2016
Steven Valentino Vice President-Trade Sales - 2017
Joanne Cotignola Vice President-Marketing - 2019
Thomas L. Long VP-Manufacturing & Technical Operations - 2017
Members of the board
Name Title Age Since
Michael J. Valentino Executive Chairman 66 2011
Natasha Giordano President, Chief Executive Officer & Director 59 2016
Gary S. Balkema Independent Director 65 2016
Kirk K. Calhoun Independent Director 76 2016
Robert Daniel Casale Independent Director 61 2016
John W. Hadden Independent Director 50 2016
Anthony Bartsh Director 41 2019
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 22,840,078 18,677,419 81.8% 0 0.0% 81.8%
Stock B 0 15,000 0 0.0% 0 0.0%
Stock C 0 8,000 0 0.0% 0 0.0%
Shareholders
NameEquities%
Level One Partners LLC 2,772,643 12.1%
Park West Asset Management LLC 2,388,475 10.5%
White Rock Capital Management LP 1,320,306 5.78%
Rosalind Advisors, Inc. 970,425 4.25%
The Vanguard Group, Inc. 947,353 4.15%
Robert D Hardie 875,000 3.83%
Michael J. Valentino 494,690 2.17%
Thompson, Siegel & Walmsley LLC 343,744 1.51%
Geode Capital Management LLC 184,366 0.81%
BlackRock Fund Advisors 46,806 0.20%
Company contact information
PLx Pharma, Inc.
9 Fishers Lane
Suite E
Sparta, NJ 07871

Phone : +1.973.409.6541
Fax : +1.973.843.6300
Web : http://www.plxpharma.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of PLx Pharma Inc.
Sector Bio Therapeutic Drugs